Adalimumab also impairs the development of Alzheimer’s disease by suppressing NF-κB, a crucial component of neuroinflammatory transcription factors, suggesting that BP-mediated inflammatory reactions might be a potential therapeutic candidate for the impairment of Alzheimer’s disease development [67]. The gene discussed is NFKB1; the disease is Alzheimer disease.